More than 30 states have enacted laws mandating use of prescription drug monitoring programs (PDMP) to reduce inappropriate opioid prescribing. Clinicians in those states must check the PDMP database before writing opioid prescriptions. These mandates vary substantially across states in their timing and scope; for example, some exempt patients with cancer.1,2 We examine the association between state mandatory-access PDMPs and changes in the percent of oncologists’ Medicare patients with any opioid prescription fills.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Graetz I, Yarbrough CR, Hu X, Howard DH. Association of Mandatory-Access Prescription Drug Monitoring Programs With Opioid Prescriptions Among Medicare Patients Treated by a Medical or Hematologic Oncologist. JAMA Oncol. Published online May 07, 2020. doi:10.1001/jamaoncol.2020.0804
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: